When the new class of GLP1 drugs like Ozempic and Wegovy came onto the market, grocery stocks took a big hit, in anticipation that people on these drugs would snack less and pull down unit sales. An overreaction to be sure, but John Carroll, President Digital Commerce and Analytic Services at Acosta Group, has spent time in CPG boardrooms discussing what the future impact and opportunities of a commercialized version of this drug might look like, and shared this point of view. Rob Gonzalez has a low opinion of humanity’s ability to let anything stand between them and their Twinkies, and this pre-thanksgiving Ozempic Hot Take podcast episode is the result.